OBJECTIVE-Ghrelin reportedly restricts insulin release in islet b-cells via the Ga i2 subtype of G-proteins and thereby regulates glucose homeostasis. This study explored whether ghrelin regulates cAMP signaling and whether this regulation induces insulinostatic cascade in islet b-cells. G hrelin, an acylated 28-amino acid peptide, is the endogenous ligand for the growth hormone secretagogue receptor (GHS-R) (1,2). Ghrelin is produced predominantly in the stomach and stimulates growth hormone release and feeding and exhibits positive cardiovascular effects, suggesting its possible clinical application (3). Ghrelin and GHS-R are located in the pancreatic islets (4-6). Furthermore, ghrelin O-acyltransferase (GOAT), which has been identified as the enzyme that promotes the acylation of the third serine residue of ghrelin, is highly expressed in the pancreatic islets (7-9). Administration of ghrelin at 10 29 -10 28 mol/L, the concentrations higher than the circulating levels of 10 210 -10 29 mol/L, attenuates insulin release and deteriorates glucose tolerance in rodents and humans, whereas desacyl ghrelin has no effects (5,10,11). This effective concentration of ghrelin that is approximately one log order higher than the circulating level is considered physiological in the pancreatic islets for the following reasons: 1) ghrelin is produced in the pancreatic islets (5), and the ghrelin level in the pancreatic vein is one log order higher than that in the pancreatic artery (12), indicative of release of ghrelin from the pancreas; 2) ghrelin immunoneutralization and GHS-R antagonists augment glucose-induced insulin release from perfused pancreas and isolated islets (5,12); and 3) ghrelin knockout mice display enhanced glucose-induced insulin release from isolated islets without altering islet density and size, insulin content, or insulin mRNA levels, indicating increased secretory activity in the knockout mouse islets (12). Furthermore, glucose intolerance in high-fat diet-induced obese (DIO) mice is prevented in the ghrelin knockout mice as a result of enhanced insulin secretory response to glucose (12). These findings suggest that the islet-derived ghrelin regulates insulin release in a paracrine and/or autocrine manner and that manipulation of the ghrelin action could provide a novel tool to optimize insulin release (13, 14) .
RESULTS-Ghrelin suppressed glucose (8.3 mmol/L)-induced insulin release in rat perfused pancreas and isolated islets, and these effects of ghrelin were blunted in the presence of cAMP analogs or adenylate cyclase inhibitor. Glucose-induced cAMP production in isolated islets was attenuated by ghrelin and enhanced by ghrelin receptor antagonist and anti-ghrelin antiserum, which counteract endogenous islet-derived ghrelin. CONCLUSIONS-Ghrelin directly interacts with islet b-cells to attenuate glucose-induced cAMP production and PKA activation, which lead to activation of Kv channels and suppression of glucoseinduced [Ca 2+ ] i increase and insulin release. Diabetes 60:2315-2324, 2011 G hrelin, an acylated 28-amino acid peptide, is the endogenous ligand for the growth hormone secretagogue receptor (GHS-R) (1, 2) . Ghrelin is produced predominantly in the stomach and stimulates growth hormone release and feeding and exhibits positive cardiovascular effects, suggesting its possible clinical application (3) . Ghrelin and GHS-R are located in the pancreatic islets (4) (5) (6) . Furthermore, ghrelin O-acyltransferase (GOAT), which has been identified as the enzyme that promotes the acylation of the third serine residue of ghrelin, is highly expressed in the pancreatic islets (7) (8) (9) . Administration of ghrelin at 10 29 -10 28 mol/L, the concentrations higher than the circulating levels of 10 210 -10 29 mol/L, attenuates insulin release and deteriorates glucose tolerance in rodents and humans, whereas desacyl ghrelin has no effects (5, 10, 11) . This effective concentration of ghrelin that is approximately one log order higher than the circulating level is considered physiological in the pancreatic islets for the following reasons: 1) ghrelin is produced in the pancreatic islets (5) , and the ghrelin level in the pancreatic vein is one log order higher than that in the pancreatic artery (12) , indicative of release of ghrelin from the pancreas; 2) ghrelin immunoneutralization and GHS-R antagonists augment glucose-induced insulin release from perfused pancreas and isolated islets (5, 12) ; and 3) ghrelin knockout mice display enhanced glucose-induced insulin release from isolated islets without altering islet density and size, insulin content, or insulin mRNA levels, indicating increased secretory activity in the knockout mouse islets (12) . Furthermore, glucose intolerance in high-fat diet-induced obese (DIO) mice is prevented in the ghrelin knockout mice as a result of enhanced insulin secretory response to glucose (12) . These findings suggest that the islet-derived ghrelin regulates insulin release in a paracrine and/or autocrine manner and that manipulation of the ghrelin action could provide a novel tool to optimize insulin release (13, 14) .
It is currently thought that GHS-R is coupled primarily to G 11 -phospholipase C signaling (2) . Intriguingly, our previous data indicated that the insulinostatic ghrelin signaling is produced via pertussis toxin (PTX)-sensitive G-protein Ga i2 in b-cells; ghrelin PTX-sensitively activates voltagedependent K + (Kv) channels, attenuates membrane excitability, and suppresses glucose-induced Ca 2+ concentration ([Ca   2+ ] i ) increases in b-cells to attenuate insulin release (15) . However, the mechanism that links GHS-R and Ga i2 to these activities in b-cells remains to be clarified. It is known that PTX-sensitive G i -proteins inhibit adenylate cyclase, which produces cyclic AMP in the cells. In pancreatic b-cells, intracellular cAMP signals are generated by nutrient secretagogues and play a critical role in regulating insulin secretion (16) (17) (18) . However, implication of cAMP signaling in the insulinostatic function of ghrelin has been unclear. In this study, we aimed to clarify whether ghrelin regulates cAMP pathway in islet b-cells and whether this regulation leads to insulinostatic cascade in islet b-cells. We here show a novel signaling mechanism for ghrelin that operates in islet b-cells; GHS-Rmediated attenuation of cAMP and protein kinase-A (PKA) signaling leads to activation of Kv channels and suppression of glucose-induced [Ca 2+ ] i increase and insulin release.
RESEARCH DESIGN AND METHODS
Male Wistar rats (Japan SLC, Hamamatsu, Japan) were housed in accordance with our institutional guidelines and with the Japanese Physiological Society's FIG. 1. Ghrelin attenuates glucose-induced insulin release in perfused rat pancreas in a cAMP pathway-dependent manner. Ghrelin was added 10 min prior to 8.3 mmol/L glucose challenge. A: Ghrelin (10 nmol/L) suppressed 8.3 mmol/L glucose (8.3G)-induced insulin release in perfused rat pancreas (n = 6). B: Ghrelin (10 nmol/L) did not alter glucose-induced insulin release from the perfused pancreas of PTX-treated rats (n = 6). C: In the presence of a 1 mmol/L dibutyryl-cAMP (db-cAMP), the glucose-induced insulin release was markedly enhanced and ghrelin failed to suppress it (n = 4-6). D: Following preincubation with an irreversible adenylate cyclase inhibitor MDL-12330A (10 mmol/L) for 30 min, the glucose-induced insulin release was attenuated and ghrelin (10 nmol/L) failed to suppress it (n = 3). E: Ghrelin (10 nmol/L) suppressed both the first and second phases of glucose-induced insulin release. In the pancreata from PTX-treated rats and those treated with a db-cAMP, both phases of glucoseinduced insulin release were markedly enhanced and ghrelin failed to alter them. In the presence of MDL-12330A, both phases of the insulin guidelines for animal care. PTX (5 mg/kg; Sigma-Aldrich, St. Louis, MO) or saline was intravenously injected into rats. Three days after injections, animals were used. In vitro perfusion of the pancreas. The rat isolated pancreas was perfused with HEPES-added Krebs-Ringer bicarbonate buffer (HKRB) solution (in millimoles per liter): 129 NaCl, 5.0 NaHCO 3 , 4.7 KCl, 1.2 KH 2 PO 4 , 2.0 CaCl 2 , 1.2 MgSO 4 , and 10 HEPES at pH 7.4 with NaOH containing 2.8 mmol/L glucose, 0.5% BSA, and 4% Dextran T70 at 37°C, as previously reported (12) . After a 20-min preincubation period, each pancreas was perfused for 10 min with 2.8 mmol/L glucose with or without test reagents. Pancreas was then perfused for 30 min with 8.3 mmol/L glucose with or without test reagents. Fractions, collected at 1-min intervals, were assayed for immunoreactive insulin. Preparation of pancreatic islets and single b-cells. Animals were anesthetized by pentobarbitone (80 mg/kg i.p.), followed by injection of collagenase at 1.05 mg/mL (Sigma-Aldrich) into the common bile duct as previously described (5, 15) . Collagenase was dissolved in 5 mmol/L Ca 2+ -containing HKRB with 0.1% BSA. The pancreas was dissected out and incubated at 37°C for 16 min. Islets were collected and used for either insulin release experiments or cAMP measurements. For b-cell experiments, islets were dispersed into single cells in Ca
2+
-free HKRB, and the single cells were plated sparsely on coverslips and maintained for 1 day at 37°C in an atmosphere of 5% CO 2 and 95% air in Eagle's minimal essential medium containing 5.6 mmol/L glucose supplemented with 10% FBS, 100 mg/mL streptomycin, and 100 units/mL penicillin. Measurements of insulin release and cAMP productions in rat islets. For measurements of islet insulin release, groups of 12-15 islets were incubated for 1 h at 37°C in HKRB with 2.8 mmol/L glucose for stabilization, followed by test incubation for 1 h in HKRB with 2.8 or 8.3 mmol/L glucose. In cAMP measurements, islets were incubated for 1 h in HKRB with 500 mmol/L 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase (PDE) inhibitor (Sigma-Aldrich), to avoid degradation of cAMP in the samples. Ghrelin (Peptide Institute, Osaka, Japan) with or without dibutyryl-cAMP (Sigma-Aldrich), 6-Phe-cAMP (BIOLOG, Bremen, Germany), and MDL-12330A (Sigma-Aldrich) was present throughout the incubation. Insulin release and total cellular cAMP content in islets were determined by ELISA (Morinaga, Yokohama, Japan) and EIA kit (GE Healthcare, Buckinghamshire, U.K.). (20) with slight modification using two-photon confocal microscopy. The DR-II-loaded islet cells were superfused in HKRB, and DR-II fluorescence was excited at 780 nm by mode-locked Ti:sapphire laser every 10 s; the emission signal at 475 nm was detected with a photomultiplier tube of the multiphoton laser-scanning microscope (FluoView FV300-TP; Olympus, Tokyo, Japan). [Ca 2+ ] i in single b-cells were measured by dual-wavelength fura-2 microfluorometry with excitation at 340/380 nm and emission at 510 nm using a cooled charge-coupled device camera (15) . The ratio image was produced on an Aquacosmos system (Hamamatsu Photonics, Hamamatsu, Japan). 
RESULTS
Ghrelin attenuates glucose-induced insulin release in a cAMP signaling-dependent manner. In rat perfused pancreas, the first and second phases of glucose (8.3 mmol/L)-induced insulin release were both significantly suppressed by exogenous ghrelin (10 nmol/L) that was administered 10 min prior to 8.3 mmol/L glucose challenge and present through the end of experiments, whereas the basal insulin release at 2.8 mmol/L glucose was not altered ( Fig. 1A and E) , confirming a previous report (15) . In perfused pancreas of PTX-treated rats, both phases of glucose-induced insulin release were markedly enhanced, and ghrelin (10 nmol/L) failed to affect them ( Fig. 1B and  E) . A membrane-permeable cAMP analog, dibutyryl-cAMP (db-cAMP), at 1 mmol/L markedly enhanced both phases of glucose-induced insulin release, and in the presence of db-cAMP ghrelin failed to suppress both phases of insulin release ( Fig. 1C and E) . In pancreas preincubated with an irreversible adenylate cyclase inhibitor, MDL-12330A (10 mmol/L), both phases of glucose-induced insulin release were attenuated and were not further altered by administration of ghrelin (10 nmol/L) ( Fig. 1D and E) . None of these treatments affected basal levels of insulin release at 2.8 mmol/L glucose. Ghrelin (10 nmol/L) affected neither acetylcholine (ACh) (10 mmol/L)-induced ( Fig. 1F and G release were suppressed, and ghrelin did not further suppress them. None of these treatments affected basal levels of insulin release at 2.8 mmol/L glucose (2.8G). *P < 0.05, **P < 0.01 vs. control; †P < 0.05, † †P < 0.01 vs. 8.3 mmol/L glucose alone (n = 3-6). Ghrelin (10 nmol/L) did not alter 10 mmol/L ACh-evoked (F and G) or 25 mmol/L KCl-evoked insulin release at 2.8 mmol/L glucose (H and I) (n = 4 for each condition). (Fig. 1H and I) . These results suggest that ghrelin selectively attenuates glucose-induced insulin release via PTX-sensitive G-protein that is coupled to modulation of cAMP signaling.
Next, in rat isolated islets, 8.3 mmol/L glucose-induced insulin release was inhibited by exogenous ghrelin (Fig. 2) . The glucose-induced insulin release was enhanced by dbcAMP (1 mmol/L). Moreover, 6-Phe-cAMP (10 mmol/L), a membrane-permeable specific PKA activator, enhanced the glucose-induced insulin release. Ghrelin (10 nmol/L) failed to attenuate the insulin release in the presence of these cAMP analogs (Fig. 2) . Conversely, the glucose-induced insulin release was significantly suppressed by adenylate cyclase inhibitor MDL-12330A (10 mmol/L), and ghrelin did not affect the insulin release in the MDL-12330A-treated islets (Fig. 2) . Ghrelin inhibits glucose-induced cAMP production in rat isolated islets. In the presence of PDE inhibitor IBMX (500 mmol/L), static incubation of islets with 8.3 mmol/L glucose induced modest cAMP productions in islets compared with those with 2.8 mmol/L glucose (P , 0.05) (Fig.  3A) . Incubation of islets with higher concentration (22 mmol/L) of glucose induced further increases in the cAMP levels. The glucose (8. (Fig. 3A) . These effects of exogenous and endogenous ghrelin were blunted in islets isolated from PTX-treated rats; neither exogenous ghrelin (10 nmol/L) nor [D-Lys 3 ]-GHRP-6 (1 mmol/L) affected the 8.3 mmol/L glucoseinduced cAMP productions, whereas 22 mmol/L glucose induced further cAMP productions (Fig. 3B) . Moreover, immunoneutralization of endogenous ghrelin with an antighrelin antiserum (0.1%) significantly enhanced the glucoseinduced cAMP productions compared with the control with a normal rabbit serum (0.1%) (Fig. 3C) . (Fig. 3D) . Ghrelin markedly suppressed the glucose-induced oscillatory rise in [cAMP] i (Fig. 3D) . Furthermore, in a MIN6 cell with pronounced oscillations of [cAMP] i during an 11 mmol/L glucose challenge, the [cAMP] i oscillations were inhibited by administration of ghrelin and recovered by its washout (Fig. 3E) , showing the reversible effect of ghrelin. Average CFP-to-YFP ratio (AUC/time) revealed that 11 mmol/L glucose increased CFP-to-YFP ratio by 19 6 4% and ghrelin significantly suppressed it (Fig. 3F) , indicating that ghrelin directly inhibits glucose-induced cAMP signaling in b-cells. Ghrelin suppresses glucose-induced PKA activation in rat b-cells. The activity of PKA, a downstream effector of cAMP elevations, was measured in rat single b-cells using PKA-sensitive DR-II fluorescence with confocal microscopy. DR-II fluorescence is inversely related to PKA activity (21) . Fluorescence intensity decreased by only 2% during scanning for 30 min, indicating that photo bleaching of DR-II signal was negligible in this experimental condition (data not shown). A rise in the perfusate glucose concentration from 2.8 to 8.3 mmol/L decreased DR-II fluorescence, as shown by an increase in F 0 -to-F ratio reflecting an increase in PKA activity in rat single b-cells (Fig. 3G) . The glucose (8.3 mmol/L)-induced increase in the PKA activity was significantly inhibited by treatment with ghrelin in the majority of b-cells examined (Fig. 3H and I) . Ghrelin activates Kv channels via PKA-dependent signaling pathway but does not alter L-type Ca 2+ channels in b-cells. The Kv channel currents in rat b-cells under nystatin-perforated whole-cell clamp were measured in the presence of 100 mmol/L tolbutamide to inhibit the ATP-sensitive K + (K ATP ) channel and thereby exclude involvement of this channel in the currents. In the presence of 8.3 mmol/L glucose, outward K + currents evoked by depolarizing pulses from a holding potential of 270 to 20 mV were increased by exposure to 10 nmol/L ghrelin (Fig. 4A) , confirming previous reports (5,15). The current-voltage relationships demonstrated that ghrelin significantly increased the current densities through Kv channels at potentials positive to 230 mV (Fig. 4B) . At a holding potential of 20 mV, ghrelin significantly increased the current densities to 125.8 6 12.6 pA/pF from 103.2 6 9.1 pA/pF (P , 0.05, n = 8) (Fig. 4D) . In the presence of 6-Phe-cAMP (10 mmol/L), the Kv channel currents evoked by depolarizing pulse to 20 mV were not increased by ghrelin (Fig. 4A) and ghrelin failed to enhance the current densities in the entire range of potentials ( Fig. 4C and D) . The Kv channel currents in the 6-Phe-cAMP-treated cells tended to decrease compared with control currents in nontreated cells (Fig. 4B and C), though the difference was not statistically significant (Fig. 4D) . We next examined the effect of 6-Phe-cAMP by itself on the b-cells. A constant depolarizing pulse from 270 to 20 mV every 20 s evoked Kv currents in the external solution containing 5.6 mmol/L glucose (Fig. 4E) . The currents markedly decreased upon exposure to 6-Phe-cAMP (10 mmol/L) and recovered by washout of it ( Fig. 4E and F) . In control experiments without the PKA activator, Kv currents were kept constant for .15 min (data not shown).
The effect of ghrelin on the voltage-dependent Ca 2+ channel was determined in rat single b-cells. In the control external solution containing 8.3 mmol/L glucose, a depolarizing pulse from holding potential of 270 to 0 mV evoked a longlasting inward current in rat b-cells (Fig. 4G ), and this current was markedly inhibited by an L-type Ca 2+ channel blocker, nifedipine (10 mmol/L) (data not shown). Exposure of cells to ghrelin (10 nmol/L) did not alter the current amplitude or current-voltage relationships ( Fig. 4G and H in the presence of PKA activator 6-Phe-cAMP at 10 mmol/L, Kv channel currents were not increased by exposure to 10 nmol/L ghrelin. B: Current levels measured at the end of test pulses were plotted as a current density (pA/pF) against membrane potentials in b-cells (n = 8). C: Ghrelin failed to potentiate Kv channel currents in the presence of 6-Phe-cAMP (n = 7). D: Peak amplitudes of current density at 20 mV of a membrane potential. Ghrelin (10 nmol/L) induced significant increase in the Kv channel currents, which was not observed in the presence of 6-Phe-cAMP. *P < 0.05 by paired t tests (n = 7-8). E: Amplitude of the Kv channel currents in a single b-cell evoked by a step pulse to 20 mV from a holding potential of 270 mV in the presence of 5.6 mmol/L glucose was decreased by 6-Phe-cAMP in a reversible manner. F: 6-Phe-cAMP (10 mmol/L) significantly decreased peak amplitude of the current density in b-cells (n = 5). *P < 0.05. G: Whole-cell Ca 2+ channel current evoked by a step pulse to 0 mV from a holding [Ca 2+ ] i response to the second glucose stimulation (S2) to that to the first stimulation (S1), S2/S1, was 0.77 6 0.04 (n = 93) in the control cells. Ghrelin (10 nmol/L), added to perfused solution 5 min prior to the second glucose stimulation, suppressed [Ca 2+ ] i responses, decreasing S2-to-S1 ratio to 0.57 6 0.04 (P , 0.01, n = 91) ( Fig. 5A and G) . The effect of ghrelin on [Ca 2+ ] i responses was abolished by treatment with db-cAMP (1 mmol/L) ( Fig. 5B and G) and 6-Phe-cAMP (10 mmol/L) ( Fig. 5C and G) . These cAMP analogs alone potentiated the glucose-induced [Ca 2+ ] i responses in b-cells, resulting in increases in S2-to-S1 ratio (Fig. 5G) . Pretreatment of cells with MDL-12330A (10 mmol/L) significantly suppressed the glucose-induced [Ca 2+ ] i increases (Fig. 5D and G) , suggesting that activation of adenylate cyclase is involved in the glucose-induced [Ca 2+ ] i increases in b-cells. In MDL-12330A-treated cells, ghrelin did not attenuate [Ca 2+ ] i responses to glucose (Fig. 5G) . The inhibitory effect of ghrelin on [Ca 2+ ] i responses was unaltered in the presence of Epac activator 8-pCPT-29-O-Me-cAMP at 30 mmol/L (Fig. 5E and G) or phospholipase-C inhibitor U-73122 (1 mmol/L) ( Fig. 5F and G) . ] i responses to ghrelin.
In rat perfused pancreas and isolated islets, the insulinostatic ability of ghrelin was blunted when cellular cAMP level was clamped upward with a cAMP analog and downward with an adenylate cyclase inhibitor. The adenylate cyclase inhibitor itself mimicked the insulinostatic ghrelin action. Ghrelin, moreover, reduced the glucoseinduced cAMP production in isolated islets, whereas blockade of endogenous ghrelin with a ghrelin receptor antagonist and an antiserum enhanced it. Since cAMP was measured in the presence of PDE inhibitor, it is likely that ghrelin affects cAMP levels primarily via interacting with the step of cAMP synthesis rather than degradation. Furthermore, evanescent-wave microscopy and two-photon confocal microscopy demonstrated that ghrelin directly interacts with MIN6 and rat b-cells to decrease glucoseinduced increases in [cAMP] i and [PKA] i .
In pancreatic b-cells, Kv channels repolarize cells and attenuate glucose-stimulated action potentials, limiting Ca 2+ entry through voltage-dependent Ca 2+ channels to suppress insulin secretion (22) . We previously reported that ghrelin activates Kv channels via PTX-sensitive mechanisms to cause rapid repolarization and shortening of bursting action potentials, thereby attenuating glucose-induced [Ca 2+ ] i increases and insulin secretion (15) . In the current study, we found that the action of ghrelin to suppress glucose-induced [Ca 2+ ] i increases was blunted in the b-cells whose cAMP levels were clamped upward by a cAMP analog and downward by an adenylate cyclase inhibitor (Fig. 5) . It is known that cAMP potentiates insulin secretion by both PKA-dependent and Epac-dependent mechanisms. 6-PhecAMP is a selective activator of PKA (23), and 8-pCPT-29-O-Me-cAMP relatively activates Epac with high affinity (24) . Ghrelin failed to suppress glucose-induced [Ca 2+ ] i increases in b-cells and insulin release in isolated islets in the presence of 6-Phe-cAMP (10 mmol/L), whereas 8-pCPT-29-O-Me-cAMP (30 mmol/L) did not alter the effect of ghrelin on [Ca 2+ ] i in b-cells. In consideration of the reports that higher concentrations of cAMP are required for activating Epac pathway (25) (26) (27) , it is likely that the glucose-induced elevation of cAMP to a moderate level in b-cells is capable of activating PKA but not Epac. Ghrelin, therefore, may attenuate [Ca 2+ ] i increases in b-cells at least partly by counteracting the glucose-stimulated cAMP and PKA signaling. However, our data with cAMP analogs cannot exclude an additional involvement of Epac in the ghrelin signaling because Epac activator used in the current study reportedly potentiates glucose-induced insulin release in a PKA--dependent manner (28) . Furthermore, potentiation of the b-cell Kv channel currents by ghrelin was blunted when PKA activity was clamped at high levels with a 6-Phe-cAMP. The PKA activator itself inhibited the channel currents (Fig. 4E) . These data suggest that ghrelin activates Kv channels by counteracting the cAMP-PKA signaling. In agreement with this finding, it has been shown that incretin hormones GLP-1, glucose-dependent insulinotropic polypeptide, and pituitary adenylate cyclase-activating polypeptide promote cAMP generation in pancreatic b-cells to potentiate insulin secretion (29) (30) (31) and that GLP-1 receptor agonist exendin-4 suppresses Kv channel currents in rat b-cells via PKAdependent and Epac-independent mechanisms (32) . Possible additional inhibitory action of ghrelin on the cAMPdependent exocytotic machinery remains to be established. It was reported that several hormone receptors of the G-protein G i/o -family regulate the K ATP channel activity and insulin exocytosis (33) (34) (35) . Whether the ghrelin action could also involve these processes remains to be studied.
We found that ghrelin selectively attenuated glucoseinduced insulin release without altering ACh-induced insulin release at 2.8 mmol/L glucose in the perfused rat pancreas. In an apparent discrepancy, ghrelin is reported to suppress carbachol-induced insulin secretion at 5.5 mmol/L glucose, a concentration over the threshold for insulin release, in the perfused rat pancreas (36) . ACh stimulates b-cells exclusively via muscarinic M 3 receptor (37,38) and induces [Ca 2+ ] i increases and insulin secretion in a glucose-dependent manner (39, 40) . Collectively, it is likely that ghrelin suppresses M 3 receptor-mediated glucose-dependent insulin release by interfering with glucose signaling but not with muscarinic receptor signaling.
It has been reported that GHS-R is coupled to G 11 -phospholipase C signaling, leading to production of inositol 1,4,5-trisphosphate (IP 3 ) and Ca 2+ release from IP 3 -sensitive stores (2) , and that ghrelin activates phospholipase-C pathway for stimulating growth hormone release in pituitary cells (41, 42) . In contrast, the mechanisms by which GHS-R activates PTX-sensitive G i -proteins ] i response to the second 8.3 mmol/L glucose stimulation (S2) to that to the first glucose stimulation (S1). The data were taken only from insulin-positive cells. *P < 0.05, **P < 0.01 vs. control; †P < 0.05, † †P < 0.01 vs. 8.3 mmol/L glucose alone (n = 66-93).
and decreases cAMP in b-cells are unclear. PTX-sensitive ghrelin signaling is reported in the guinea pig femoral artery smooth muscle cells (43) . G-protein-coupled receptors often activate more than one type of G-protein (44) . Hence, the ghrelin interaction with GHS-R could activate distinct classes of G-protein signaling including G 11 -and G i -mediated pathways in a tissue-specific manner. Alternatively, the isoforms of GHS-R (45, 46) or heterodimer of GHS-R with other receptors (47) could access the G iprotein complex. The ghrelin receptor in b-cells remains to be further characterized.
In conclusion, ghrelin attenuates the glucose-induced cAMP production and PKA activation, which drives activation of Kv channels and suppression of the glucoseinduced [Ca 2+ ] i increase and insulin release. This is a novel ghrelin signaling that operates in islet b-cells, being distinct from that reported in other tissues including pituitary growth hormone cells. It has been shown that ghrelin receptor antagonists and GOAT inhibitor increase the insulin release and decrease blood glucose in glucose tolerance tests, thereby acting as antidiabetic (5, 12, 15, (48) (49) (50) . The current study demonstrated that the ghrelin's signaling cascade and consequent inhibition of insulin release are mediated by attenuation of the cAMP pathway. Hence, counteracting the attenuation of cAMP could provide a new strategy to counteract insulinostatic ghrelin action and thereby to treat type 2 diabetes.
